23 completed, 5 terminated, 4 recruiting, 4 unknown. 15 Phase 1, 9 Phase 3, 8 Phase 2, 6 Not applicable.
Follow Stage III Colon Cancer: new trials by email Literature Review of Stage III Colon Cancer trials Research Report on Stage III Colon Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points - Colon Adenocarcinoma, Stage I Colon Cancer | Recruiting | Ruijin Hospital | 392 | 2026-08-14 | 2026-09-02 | |
| Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2 - Stage I Colon Cancer, Stage II Colon Cancer | Phase 2 | Recruiting | Baylor College of Medicine | 28 | 2025-06-15 | 2025-05-25 |
| French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) Blood sample/lliquid biopsy - Colorectal Cancer, Stage III Colon Cancer | Recruiting | University Hospital, Montpellier | 70 | 2024-04-11 | 2026-08-18 | |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer | Phase 2 | Suspended | Gruppo Oncologico del Nord-Ovest | 477 | 2023-05-17 | 2026-02-03 |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month - Stage III Colon Cancer | Phase 2 / Phase 3 | Recruiting | NRG Oncology | 1912 | 2022-07-08 | 2026-11-04 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Bevacizumab, Dasatinib, Fluorouracil - Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 | Completed | Anne Noonan | 9 | 2020-09-02 | 2024-12-27 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Binimetinib, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Terminated | University of California, San Francisco | 2 | 2020-08-31 | 2023-01-09 |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol - Metastatic Colon Cancer, Stage III Colon Cancer | Phase 3 | Active not recruiting | Massachusetts General Hospital | 400 | 2020-04-16 | 2026-09-09 |
| Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer Stage II Colon Cancer, Stage III Colon Cancer | Active not recruiting | Boryung Pharmaceutical Co., Ltd | 2013 | 2020-03-25 | 2025-09-12 | |
| Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery Stage II Colon Cancer, Stage III Colon Cancer | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 20000 | 2018-11-09 | 2021-07-15 | |
| Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer Avelumab - POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability | Phase 3 | Terminated | Royal Marsden NHS Foundation Trust | 30 | 2018-08-31 | 2022-10-07 |
| LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy Oxaliplatin, Oxaliplatin LBM - Stage III Colon Cancer | Phase 2 | Completed | Institut du Cancer de Montpellier - Val d'Aurelle | 160 | 2017-11-01 | 2026-11-09 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment Immunoscore test - Colorectal Cancer, Stage III Colon Cancer | Unknown | GERCOR - Multidisciplinary Oncology Cooperative Group | 1122 | 2017-07-13 | 2019-02-27 | |
| Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection tegafur-uracil - Stage III Colon Cancer | Not applicable | Unknown | Kaohsiung Medical University Chung-Ho Memorial Hospital | 400 | 2016-03-01 | 2017-02-08 |
| Exercise and Colon Cancer Exercise - Stage II Colon Cancer, Stage III Colon Cancer | Not applicable | Completed | Abramson Cancer Center at Penn Medicine | 44 | 2015-12-01 | 2020-04-09 |
| Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer questionnaire administration, laboratory biomarker analysis, Standard Dietary Intervention - Stage I Colon Cancer, Stage II Colon Cancer | Not applicable | Completed | Case Comprehensive Cancer Center | 18 | 2015-02-16 | 2018-07-20 |
| Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy Radical surgery, Adjuvant chemotherapy, Cytokine-induced killer cell immunotherapy - Stage III Colon Cancer | Phase 3 | Unknown | Sun Yat-sen University | 550 | 2014-10-01 | 2014-11-05 |
| Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer AVX701 - Stage III Colon Cancer | Phase 1 | Completed | Duke University | 12 | 2013-11-01 | 2019-07-18 |
| Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer defined green tea catechin extract, placebo, questionnaire administration - Advanced Colorectal Adenomas, Adenocarcinoma of the Colon | Phase 2 | Terminated | Mayo Clinic | 39 | 2012-06-01 | 2017-10-27 |
Showing 20 of 39. Sign in to see all of them.
Colonic Neoplasms (39) · Rectal Neoplasms (18) · Pancreatic Neoplasms (8) · Stomach Neoplasms (7) · Colorectal Neoplasms (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms, Male (4) · Carcinoma, Ovarian Epithelial (4) · Carcinoma, Renal Cell (4) · Gallbladder Neoplasms (4) · Salivary Gland Neoplasms (4) · Appendiceal Neoplasms (3) · Bile Duct Neoplasms (3) · Carcinoma, Hepatocellular (3)
Colonic Diseases (39) · Digestive System Diseases (39) · Digestive System Neoplasms (39) · Gastrointestinal Diseases (39) · Intestinal Diseases (39) · Intestinal Neoplasms (39) · Neoplasms by Site (39) · Gastrointestinal Neoplasms (38) · Neoplasms (38) · Colorectal Neoplasms (33) · Rectal Diseases (21) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Neoplasms by Histologic Type (8) · Pancreatic Diseases (8)
Fluorouracil (9) · Leucovorin (9) · Oxaliplatin (8) · Irinotecan (6) · Bevacizumab (4) · Capecitabine (4) · Cetuximab (4) · Trastuzumab (3) · Nivolumab (2) · encorafenib (2) · pertuzumab (2) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 2C4 antibody (1) · Blood Specimen Collection (1)
National Cancer Institute (NCI) (17) · Abramson Cancer Center at Penn Medicine (1) · Anne Noonan (1) · Baylor College of Medicine (1) · Boryung Pharmaceutical Co., Ltd (1) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Duke University (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · Gruppo Oncologico del Nord-Ovest (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Kaohsiung Medical University Chung-Ho Memorial Hospital (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · NRG Oncology (1)
United States (29) · Canada (3) · China (3) · France (3) · Puerto Rico (2) · Italy (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Alain Mita (1) · Anne M Noonan, MBBChBAO, MSc (1) · Aparna Parikh, MD (1) · Atif Iqbal, MD (1) · Bruce Giantonio (1) · Charles Blanke (1) · Chloe E Atreya, MD, PhD (1) · David Solit (1) · Dean Brenner (1) · Frank Sinicrope (1) · James Abbruzzese (1) · John Kuebler (1) · Kathryn Schmitz, PhD (1) · Kimmie Ng (1)
PMID 21997132, PMID 31268130, PMID 33356421, PMID 17470851, PMID 17853393, PMID 20052723, PMID 20233444, PMID 21859995, PMID 22474202, PMID 23623224, PMID 24220557, PMID 24231454, PMID 24987057, PMID 25310185, PMID 27270348, PMID 28006055, PMID 28327908, PMID 28441966, PMID 28983557, PMID 29489429, PMID 29710284, PMID 30038051, PMID 30826660, PMID 31811950, PMID 32079623, PMID 32085892, PMID 32165096, PMID 32294529, PMID 33142018, PMID 33203692, PMID 33863713, PMID 34749008, PMID 35412430, PMID 35641198, PMID 35771552, PMID 35963480, PMID 36306483, PMID 38148846, PMID 38315963, PMID 40540704
N01CM17003 (1), P01CA087971 (1), P30CA014520 (1), P30CA043703 (1), P30CA046592 (1), P30CA054174 (1), R21CA117125 (1), U01CA062490 (1), U01CA062491 (1), U01CA069853 (1), U01CA069856 (1), U01CA070095 (1), U01CA076576 (1), U01CA132123 (1), U10CA012027 (1)